OmniCyte Founder, Peter Leonardi, provides insight into the emerging field of immunotherapy. Immunotherapy is the process that uses the body’s natural defense system to cure cancer. The most popular area is in […]
DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.
Cancer drug sales are slowing down in the U.S., Reuters reported Monday.
China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.
A brain cancer vaccine from Immunocellular Therapeutics has yielded positive results in a small Phase I clinical trial.
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.